Safety and efficacy of linaclotide in children aged 2-5 years with functional constipation: Phase 2, randomized study

Area of Science:

• Pediatric Gastroenterology
• Pharmacology
• Clinical Trial Research

Background:

• Functional constipation (FC) is a common gastrointestinal disorder in children.
• Linaclotide, a guanylate cyclase-C agonist, is approved for older children (6-17 years) with FC.
• The efficacy and safety of linaclotide in younger children (2-5 years) with FC require further investigation.

Purpose of the Study:

• To evaluate the dose-response, safety, and efficacy of linaclotide in children aged 2-5 years with functional constipation.
• To compare linaclotide treatment with placebo over a 4-week period.
• To assess key endpoints including spontaneous bowel movement frequency, stool consistency, straining, and fecal incontinence.

Main Methods:

• A phase 2, randomized, double-blind, placebo-controlled, multidose study.
• 35 children with FC (Rome III criteria) were randomized to receive linaclotide (9-72 μg) or placebo.
• Efficacy endpoints included changes in SBM frequency, stool consistency, straining, and fecal incontinence; adverse events were recorded.

Main Results:

• 34 out of 35 patients completed the study.
• The linaclotide 72 μg group showed greater improvement in three of four key efficacy endpoints compared to placebo.
• A dose-response trend was observed for stool consistency; treatment-emergent adverse events were mild or moderate, with one case of mild diarrhea.

Conclusions:

• Linaclotide was well-tolerated in children aged 2-5 years with functional constipation.
• An efficacy trend was observed with linaclotide 72 μg compared to placebo.
• Further research may explore the optimal dosing and long-term effects in this pediatric age group.